Traditional dissolution methods do not include bioactive components within their methodologies. Although helpful for the dissolution of soluble tablets and other classes of APIs, prodrugs require active enzyme in order to exhibit their mechanism of action (aka biotransformation). We have previously developed an in vitro instrument, termed the subcutaneous injection site simulator (SCISSOR), which offers a dynamic environment to assay injectable pharmaceuticals to overcome this barrier.
At the heart of the SCISSOR platform lies an artificial extracellular matrix, suited for the non-destructive suspension of biomolecules. Within this webinar we look to describe how we conserve biorelevant enzymatic activity within the SCISSOR N3, expanding the application space of acellular in vitro methods to include characterizing the behavior of prodrug formulations before, during, and after biotransformation.
